Drug profile

Testosterone undecanoate

CAS No.5949-44-0
ATCG03BA03
Therapeutic areaEndocrinology / Male hypogonadism
OriginatorClarus Therapeutics / current product holder
GenericRadar assessment

Patent Radar Assessment

Grade A2 United States · 2030 Radar
Verification HIGH
Why Grade A?

FDA Orange Book data lists US10617696 as a Drug Substance/Drug Product patent for JATENZO expiring 2030-04-12.

Core Patent Expiry 2030-04-12
2030 Target Event US10617696
Drug Substance / Drug Product · 2030-04-12
Core API Event? Yes
Later Blocking Patents

Yes. JATENZO has use patents extending to 2039; other 2030 product/use patents also exist.

Generic Entry Assessment

2030 DS milestone is real, but testosterone undecanoate itself is an older active ingredient and this assessment is product-specific to JATENZO patent coverage.

Patent landscape

CountryPatent no.TypeExpiryStatusVerifiedOpportunity
United StatesUS10617696Drug Substance / Drug Product2030-04-12ProtectedYes68

API sourcing

Regulatory filing labels distinguish verified/listed records from records that have not yet been verified. “Not verified” does not mean that a filing does not exist.

APIManufacturerCountry US DMFKDMFJapan MFCEPEU GMPStatus
Testosterone undecanoate Aspen API Netherlands ✓ Listed Not verified Not verified Not verified Not verified Active US DMF
Testosterone undecanoate Bayer AG Germany ✓ Active · 16795 Not verified Not verified Not verified Not verified Active US DMF
Testosterone undecanoate Hubei Zhuxi Humanwell Pharmaceutical China ✓ Active · 40120 Not verified Not verified Not verified Not verified Active US DMF
Testosterone undecanoate Pfizer CentreOne United States ✓ Active · 24500 Not verified Not verified Not verified Not verified Active US DMF
Testosterone undecanoate Symbiotec Pharmalab India ✓ Listed Not verified Not verified Not verified Not verified Active US DMF
Testosterone undecanoate Zhejiang Xianju Pharmaceutical Co. Ltd China ✓ Active · 23934 Not verified Not verified Not verified Not verified Active US DMF